WO1998049300A3 - Truncated vegf-related proteins - Google Patents

Truncated vegf-related proteins Download PDF

Info

Publication number
WO1998049300A3
WO1998049300A3 PCT/US1998/007801 US9807801W WO9849300A3 WO 1998049300 A3 WO1998049300 A3 WO 1998049300A3 US 9807801 W US9807801 W US 9807801W WO 9849300 A3 WO9849300 A3 WO 9849300A3
Authority
WO
WIPO (PCT)
Prior art keywords
vrps
truncated
related proteins
useful
nucleic acids
Prior art date
Application number
PCT/US1998/007801
Other languages
French (fr)
Other versions
WO1998049300A2 (en
Inventor
Peter Bohlen
Original Assignee
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collateral Therapeutics filed Critical Collateral Therapeutics
Priority to EA199900861A priority Critical patent/EA199900861A1/en
Priority to EP98919794A priority patent/EP0977854A2/en
Priority to JP54706298A priority patent/JP2001524828A/en
Priority to NZ500530A priority patent/NZ500530A/en
Priority to AU72502/98A priority patent/AU7250298A/en
Priority to CA002287538A priority patent/CA2287538A1/en
Priority to IL13253798A priority patent/IL132537A0/en
Publication of WO1998049300A2 publication Critical patent/WO1998049300A2/en
Publication of WO1998049300A3 publication Critical patent/WO1998049300A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

The present invention provides novel truncated forms of vascular endothelial growth factor-related proteins (VRPs or VRPs) which are useful for the stimulation of angiogenesis in vitro and in vivo. The invention also provides nucleic acids encoding such novel truncated VRPs and methods of producing truncated VRPs. Pharmaceutical compositions comprising truncated VRPs and methods of gene therapy using the nucleic acids which code for truncated VRPs may be useful for the treatment of heart disease and for wound healing.
PCT/US1998/007801 1997-04-25 1998-04-20 Truncated vegf-related proteins WO1998049300A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA199900861A EA199900861A1 (en) 1997-04-25 1998-04-20 TRACKED PROTEINS, RELATED GROWTH ENDOTHELIUM GROWTH FACTOR
EP98919794A EP0977854A2 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins
JP54706298A JP2001524828A (en) 1997-04-25 1998-04-20 Truncated VEGF-related protein
NZ500530A NZ500530A (en) 1997-04-25 1998-04-20 Truncated VEGF-B, VEGF-C, VEGF-3, PlGF, VRF-2, poxvirus ORF-1 and ORF-2 proteins
AU72502/98A AU7250298A (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins
CA002287538A CA2287538A1 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins
IL13253798A IL132537A0 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
US08/842,984 1997-04-25

Publications (2)

Publication Number Publication Date
WO1998049300A2 WO1998049300A2 (en) 1998-11-05
WO1998049300A3 true WO1998049300A3 (en) 1999-03-11

Family

ID=25288752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007801 WO1998049300A2 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Country Status (10)

Country Link
EP (1) EP0977854A2 (en)
JP (1) JP2001524828A (en)
KR (1) KR20010020259A (en)
CN (2) CN1260835A (en)
AU (1) AU7250298A (en)
CA (1) CA2287538A1 (en)
EA (1) EA199900861A1 (en)
IL (1) IL132537A0 (en)
NZ (2) NZ514872A (en)
WO (1) WO1998049300A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CA2184584C (en) 1994-03-08 2003-04-08 Jing-Shan Hu Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
EP1382679A3 (en) 1995-09-08 2004-11-10 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
AU3072099A (en) * 1998-03-13 1999-09-27 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DE19813774A1 (en) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapox virus-encoded vascular endothelial cell growth factor (PPV-VEGF)
CA2331601A1 (en) * 1998-03-27 1999-10-07 Charles Little Vegf and vegf-c as infant formula supplements
WO2000014105A1 (en) 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
EP1568375A1 (en) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
WO2000024412A2 (en) * 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ES2316194T3 (en) 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. METHODS FOR THE REGULATION OF ANGIOGENESIS AND VASCULAR INTEGRITY USING THE BDNF, NT-3 AND NT-4 LIGANDS.
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
WO2001057181A2 (en) * 2000-02-04 2001-08-09 Carmeliet, Peter Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
CA2405291A1 (en) * 2000-04-06 2001-10-18 Wayne P. Franco Methods of using growth factors for treating heart disease
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
EP1313512A4 (en) 2000-08-04 2004-08-25 Human Genome Sciences Inc Vascular endothelial growth factor 2
WO2002014367A1 (en) 2000-08-10 2002-02-21 Center For Advanced Science And Technology Incubation,Ltd. Chimeric human-type vascular endothelial cell growth factor
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7709450B2 (en) 2001-06-20 2010-05-04 Ludwig Institute For Cancer Research Stimulation of vascularization with VEGF-B-186
DE60216310T2 (en) 2001-10-15 2007-06-21 Janssen Pharmaceutica N.V. SUBSTITUTED 4-PHENYL-4- (1H-IMIDAZOLE-2-YL) -PIPERIDINE DERIVATIVES TO REDUCE ISCHEMIC INJURY
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006194A1 (en) * 1990-09-27 1992-04-16 Consiglio Nazionale Delle Ricerche Nucleotide sequences coding for a human protein with angiogenesis regulative properties
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
WO1996027007A1 (en) * 1995-03-02 1996-09-06 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1996026736A1 (en) * 1995-03-01 1996-09-06 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
WO1997005250A2 (en) * 1995-08-01 1997-02-13 Helsinki University Licensing Ltd. Oy Receptor ligand vegf-c

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006194A1 (en) * 1990-09-27 1992-04-16 Consiglio Nazionale Delle Ricerche Nucleotide sequences coding for a human protein with angiogenesis regulative properties
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1996026736A1 (en) * 1995-03-01 1996-09-06 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b
WO1996027007A1 (en) * 1995-03-02 1996-09-06 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
WO1997005250A2 (en) * 1995-08-01 1997-02-13 Helsinki University Licensing Ltd. Oy Receptor ligand vegf-c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEPPER M.S. ET AL.: "Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 189, no. 2, 15 December 1992 (1992-12-15), pages 824 - 831, XP002078851 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Also Published As

Publication number Publication date
KR20010020259A (en) 2001-03-15
NZ514872A (en) 2005-01-28
CA2287538A1 (en) 1998-11-05
EA199900861A1 (en) 2000-06-26
EP0977854A2 (en) 2000-02-09
CN1680442A (en) 2005-10-12
AU7250298A (en) 1998-11-24
CN1260835A (en) 2000-07-19
JP2001524828A (en) 2001-12-04
IL132537A0 (en) 2001-03-19
WO1998049300A2 (en) 1998-11-05
NZ500530A (en) 2001-12-21

Similar Documents

Publication Publication Date Title
WO1998049300A3 (en) Truncated vegf-related proteins
WO2004061456A3 (en) Uses of hmgb, hmgn, hmga proteins
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
WO2002014358A3 (en) Novel secreted proteins and their uses
IL150566A0 (en) Nucleic acids and polypeptides and nogo-receptor proteins
PT1232264E (en) Human fgf-21 gene and gene expression products
WO2001062794A3 (en) 18607, a human calcium channel
IL112873A (en) Rapamycin-fkbp12 binding proteins, their isolation and their use
WO2000024412A3 (en) Use of vegf-c or vegf-d gene or protein to prevent restenosis
WO1995025171A3 (en) Dna sequences for matrix metalloproteases, their production and use
DK1025237T3 (en) Human checkpoint kinase, hCDS1, preparations and methods
WO2002050111A3 (en) Isolated laminin 10
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
WO2002032939A3 (en) Secreted proteins and their uses
DK0781344T3 (en) Newly known implant and novel vector for the treatment of acquired diseases
DK1165102T3 (en) Matrix protein preparations for grafting in non-mineralized tissue
HUP0202974A2 (en) Metal-containing ribonucleotide polypeptides
WO2002026801A3 (en) Secreted proteins and their uses
WO2002048361A3 (en) Novel secreted proteins and their uses
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
WO1998054209A3 (en) Human mast cell function-associated antigen (mafa) and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 132537

Country of ref document: IL

Ref document number: 98806232.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 500530

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2287538

Country of ref document: CA

Ref document number: 2287538

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 199900861

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 1998 547062

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998919794

Country of ref document: EP

Ref document number: 1019997009857

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 72502/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998919794

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997009857

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019997009857

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998919794

Country of ref document: EP